NCT03005132
Recruiting
Not Applicable
Integrative Analysis of Human Glioblastoma Multiforme
Shanghai 10th People's Hospital1 site in 1 country1,000 target enrollmentJanuary 2016
ConditionsGBM
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- GBM
- Sponsor
- Shanghai 10th People's Hospital
- Enrollment
- 1000
- Locations
- 1
- Primary Endpoint
- 5 years overall survival
- Status
- Recruiting
- Last Updated
- 9 years ago
Overview
Brief Summary
Integrative analysis of GBM
Detailed Description
The investigators will analyzed proteomes of paired normal brain tissues and GBM, sequenced transcriptomes, perform whole exome sequencing, and single nucleotide polymorphism (SNP) array profiling for triplets, each comprising normal brain tissue, primary GBM carcinoma, and its synchronous matched metastasis, as well as analyzed genomics of GBM characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses.
Investigators
Da Fu
Principal Investigator
Shanghai 10th People's Hospital
Eligibility Criteria
Inclusion Criteria
- •Age ≤ 75 years with histologically proven GBM
- •No severe major organ dysfunction
- •World Health Organization (WHO) performance status of 0 or 1
- •No prior cancer chemotherapy
Exclusion Criteria
- •Severe major organ dysfunction
- •WHO performance status of \>1
- •Prior cancer chemotherapy
Outcomes
Primary Outcomes
5 years overall survival
Time Frame: 5 years
Secondary Outcomes
- 5 years disease-free survival(5 years)
- 10 years overall survival(10 years)
- 10 years disease-free survival(10 years)
Study Sites (1)
Loading locations...
Similar Trials
Terminated
Not Applicable
Spatial Analysis and Validation of Glioblastoma on 7 T MRIGlioblastomaNCT02062372Maastricht Radiation Oncology5
Terminated
Not Applicable
Study Using Genomic, Histologic and Radiomic Analysis to Evaluate Regional Tumor Heterogeneity in Patients Undergoing Surgery for Newly Diagnosed GlioblastomaGlioblastomaNCT03287063University of Michigan Rogel Cancer Center6
Completed
Phase 1
Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed GlioblastomaGlioblastomaNCT03466450Grupo Español de Investigación en Neurooncología75
Completed
Not Applicable
Determination of Immune Phenotype in Glioblastoma PatientsGlioblastoma MultiformeNCT02751138University of Ulm100
Completed
Not Applicable
Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma MultiformeGlioblastomaNCT01604590Medical University of South Carolina13